 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by John Corboy and Andrew Wolf.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.450 |
|
|
|
-
Wolf AB, Corboy JR. Escalation to Anti-CD20 Treatment for Multiple Sclerosis Following Natalizumab-Associated Progressive Multifocal Leukoencephalopathy. Neurol Clin Pract. 2024 Oct; 14(5):e200330.
Score: 0.908
-
Wolf AB, Alvarez E, Corboy JR. Comparative Efficacy of Disease-Modifying Treatments for Relapsing Multiple Sclerosis-Variations in Real-World Experience. JAMA Neurol. 2024 01 01; 81(1):87.
Score: 0.881
-
Ardakani RV, Crane PD, Pastula DM, Chauhan L, Matthews E, Money KM, Shah A, Piquet AL, Gross RH, Carlson AM, Tyler KL, Corboy JR, Alvarez E, Wolf AB. West Nile Virus Neuroinvasive Disease in Patients Treated With Anti-CD20 Therapies. Neurol Clin Pract. 2025 Aug; 15(4):e200489.
Score: 0.244
-
Shah AA, Wolf AB, Declusin A, Coleman K, Kammeyer R, Khan B, Corboy JR. Challenging Cases in Neuroimmunology. Semin Neurol. 2022 12; 42(6):695-707.
Score: 0.206
-
Wolf AB, Ryerson LZ, Pandey K, McGettigan BM, Vollmer T, Corboy JR, Alvarez E. Rituximab-induced serum sickness in multiple sclerosis patients. Mult Scler Relat Disord. 2019 Nov; 36:101402.
Score: 0.164
-
Vollmer BL, Wolf AB, Sillau S, Corboy JR, Alvarez E. Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple Sclerosis. Front Neurol. 2021; 12:799138.
Score: 0.048
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|